Crystal structure of deglycosylated human IgG4-Fc

Molecular Immunology

Volumn 62, Issue 1, 2014, Pages 46-53

  Davies, Anna M ^a,b   Jefferis, Roy ^c   Sutton, Brian J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antibody; Complement; Fc receptor; Fc Fc interaction; Glycosylation; Immunoglobulin

Indexed keywords

COMPLEMENT COMPONENT C1Q; DEGLYCOSYLATED IMMUNOGLOBULIN G4 FC; FC RECEPTOR; IMMUNOGLOBULIN G4; OLIGOSACCHARIDE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PROTEIN BINDING;

ANTIBODY RESPONSE; ANTIBODY STRUCTURE; ARTICLE; COMPLEMENT FIXATION; CRYSTAL STRUCTURE; HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; RECEPTOR BINDING; CHEMICAL STRUCTURE; CHEMISTRY; GLYCOSYLATION; METABOLISM; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84902684505     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.05.015     Document Type: Article

References (65)

1. Aalberse R.C., Schuurman J. IgG4 breaking the rules. Immunology 2002, 105:9-19.
2. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 2009, 39:469-477.
3. Abès R., Teillaud J.-L. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 2010, 3:146-157.
4. Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.-W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
5. Baruah K., Bowden T.A., Krishna B.A., Dwek R.A., Crispin M., Scanlan C.N. Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J. Mol. Biol. 2012, 420:1-7.
6. Borrok M.J., Jung S.T., Kang T.H., Monzingo A.F., Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 2012, 7:1596-1602.
7. Bowden T.A., Baruah K., Coles C.H., Harvey D.J., Yu X., Song B.D., Stuart D.I., Aricescu A.R., Scanlan C.N., Jones E.Y., Crispin M. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J. Am. Chem. Soc. 2012, 134:17554-17563.
8. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilge M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography & NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 1998, 54:905-921.
9. Burton D.R. Antibody: the flexible adaptor molecule. Trends Biochem. Sci. 1990, 15:64-69.
10. Canfield S.M., Morrison S.L. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 1991, 173:11483-11491.
11. Chen V.B., Arendall W.B., Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., Murray L.W., Richardson J.S., Richardson D.C. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:12-21.
12. Corper A.L., Sohi M.K., Bonagura V.R., Steinitz M., Jefferis R., Feinstein A., Beale D., Taussig M.J., Sutton B.J. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat. Struct. Biol. 1997, 4:374-381.
13. Crispin M., Bowden T.A., Coles C.H., Harlos K., Aricescu A.R., Harvey D.J., Stuart D.I., Jones E.Y. Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. J. Mol. Biol. 2009, 387:1061-1066.
14. Davies A.M., Rispens T., den Bleker T.H., McDonnell J.M., Gould H.J., Aalberse R.C., Sutton B.J. Crystal structure of the human IgG4 CH3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Mol. Immunol. 2013, 54:1-7.
15. Davies A.M., Rispens T., Ooijevaar-de Heer P., Gould H.J., Jefferis R., Aalberse R.C., Sutton B.J. Structural determinants of unique properties of human IgG4-Fc. J. Mol. Biol. 2014, 426:630-644.
16. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8Å resolution. Biochemistry 1981, 20:2361-2370.
17. DeLano W.L., Ultsch M.H., de Vos A.M., Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287:1279-1283.
18. Diebolder C.A., Beurskens F.J., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J.R., van de Winkel J.G.J., Wilson I.A., Koster A.J., Taylor R.P., Ollmann Saphire E., Burton D.R., Schuurman J., Gros P., Parren P.W.H.I. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
19. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
20. Evans P.R., Murshudov G.N. How good are my data and what is the resolution?. Acta Crystallogr. D Biol. Crystallogr. 2013, 69:1204-1214.
21. Feige M.J., Nath S., Catharino S.R., Weinfurtner D., Steinbacher S., Buchner J. Structure of the murine unglycosylated IgG1 Fc fragment. J. Mol. Biol. 2009, 391:599-608.
22. Ferrara C., Grau S., Jäger C., Sondermann P., Brünker P., Waldhauer I., Hennig M., Ruf A., Rufer A.C., Stihle M., Umaña P., Benz J. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12669-12674.
23. Forthal D.N., Gach J.S., Landucci G., Jez J., Strasser R., Kunert R., Steinkellner H. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 2010, 185:6876-6882.
24. Frank M., Walker R.C., Lanzilotta W.N., Prestegard J.H., Barb A.W. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J. Mol. Biol. 2014, 10.1016/j.jmb.2014.01.011.
25. Gaboriaud C., Frachet P., Thielens N.M., Arlaud G.J. The human C1q globular domain: structure and recognition of non-immune self ligands. Front. Immunol. 2012, 2:92.
26. Ghai R., Waters P., Roumenina L.T., Gadjeva M., Kojouharova M.S., Reid K.B.M., Sim R.B., Kishore U. C1q and its growing family. Immunobiology 2007, 212:253-256.
27. Ghirlando R., Lund J., Goodall M., Jefferis R. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol. Lett. 1999, 68:47-52.
28. Girardi E., Holdom M.D., Davies A.M., Sutton B.J., Beavil A.J. The crystal structure of rabbit IgG-Fc. Biochem. J. 2009, 417:77-83.
29. Halaby D.M., Poupon A., Mornon J. The immunoglobulin fold family: sequence analysis and 3D structure comparisons. Protein Eng. 1999, 12:563-571.
30. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin M.G. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164:4178-4184.
31. James L.C., Keeble A.H., Khan Z., Rhodes D.A., Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. U.S.A. 2007, 107:6200-6205.
32. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 2009, 30:356-362.
33. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 2012, 526:159-166.
34. Jefferis R., Lund J., Mizutani H., Nakagawa H., Kawazoe Y., Arata Y., Takahashi N. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J. 1990, 268:529-537.
35. Kabsch W. XDS. Acta Crystallogr. D Biol. Crystallogr. 2010, 69:125-132.
36. Kanda Y., Yamada T., Mori K., Okazaki A., Inoue M., Kitajima-Miyama K., Kuni-Kamochi R., Nakano R., Yano K., Kakita S., Shitara K., Satoh M. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2006, 17:104-118.
37. Kolenko P., Dohnálek J., Dušková J., Skálová T., Collard R., Hašek J. New insights into intra and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2.1-Å resolution. Immunology 2009, 126:378-385.
38. Krapp S., Mimura Y., Jefferis R., Huber R., Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325:979-989.
39. Kuznetsov Y.G., Day J., Newman R., McPherson A. Chimeric human-simian anti-CD4 antibodies form crystalline high symmetry particles. J. Struct. Biol. 2000, 131:108-115.
40. Labrijn A.F., Ortiz Buijsse A., van den Bremer E.T.J., Verwilligen A.Y.W., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., van de Winkel J.G.J., Parren P.W.H.I. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 2009, 27:767-771.
41. Labrijn A.F., Rispens T., Meesters J., Rose R.J., den Bleker T.H., Loverix S., van den Bremer E.T.J., Neijssen J., Vink T., Lasters I., Aalberse R.C., Heck A.J.R., van de Winkel J.G.J., Schuurman J., Parren P.W.H.I. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J. Immunol. 2011, 187:3238-3246.
42. Martin W.L., West A.P., Gan L., Bjorkman P.J. Crystal structure at 2.8Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 2001, 7:867-877.
43. Matsumiya S., Yamaguchi Y., Saito J., Nagano M., Sasakawa H., Otaki S., Satoh M., Shitara K., Kato K. Corrigendum to "Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1" [J Mol. Biol. 386 (3) (2007) 767-779]. J. Mol. Biol. 2011, 408:1001.
44. Mizushima T., Yagi H., Takemoto E., Shibata-Koyama M., Isoda Y., Iida S., Masuda K., Satoh M., Kato K. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011, 16:1071-1080.
45. Müller R., Gräwert M.A., Kern T., Madl T., Peschek J., Sattler M., Groll M., Buchner J. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:10183-10188.
46. Parekh R., Isenberg D., Rook G., Roitt I., Dwek R., Rademacher T. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J. Autoimmun. 1989, 2:101-114.
47. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., Sun P.D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 2001, 276:16469-16477.
48. Randall T.D., King L.B., Corley R.B. The biological effects of IgM hexamer formation. Eur. J. Immunol. 1990, 20:1971-1979.
49. Ramsland P.A., Farrugia W., Bradford T.M., Sardjono C.T., Esparon S., Trist H.M., Powell M.S., Tan P.S., Cendron A.C., Wines B.D., Scott A.M., Hogarth P.M. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 2011, 187:3208-3217.
50. Rispens T., Ooijevaar-de Heer P., Bende O., Aalberse R.C. Mechanism of immunoglobulin G4 Fab-arm exchange. J. Am. Chem. Soc. 2011, 133:10302-10311.
51. Rose R.J., Labrijn A.F., van den Bremer E.T.J., Loverix S., Lasters I., van Berkel P.H.C., van de Winkel J.G.J., Schuurman J., Parren P.W.H.I., Heck A.J.R. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011, 19:1274-1282.
52. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., Wilson I.A. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.
53. Sauer-Eriksson A.E., Kleywegt G.J., Uhlén M., Jones T.A. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 1995, 3:265-278.
54. Schneider S., Zacharias M. Atomic resolution model of the antibody Fc interaction with the complement C1q component. Mol. Immunol. 2012, 51:66-72.
55. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000, 406:267-273.
56. Sprague E.R., Wang C., Baker D., Bjorkman P.J. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. 2006, 4:e148.
57. Tao M.H., Smith R.I.F., Morrison S.L. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 1993, 178:661-667.
58. 3 interface. Mol. Immunol. 2013, 56:131-139.
59. Tomana M., Schrohenloher R.E., Koopman W.J., Alarcón G.S., Paul W.A. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 1988, 31:333-338.
60. Urzhumtseva L., Afonine P.V., Adams P.D., Urzhumtsev A. Crystallographic model quality at a glance. Acta Crystallogr. D Biol. Crystallogr. 2009, 65:297-300.
61. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
62. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G.J., Aalberse R.C., Parren P.W.H.I. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab-arm exchange. Science 2007, 317:1554-1557.
63. Winn M.D., Ballard C.C., Cowtan K.D., Dodson E.J., Emsley P., Evans P.R., Keegan R.M., Krissinel E.B., Leslie A.G.W., McCoy A., McNicholas S.J., Murshudov G.N., Pannu N.S., Potterton E.A., Powell H.R., Read R.J., Vagin A., Wilson K.S. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 2011, 67:235-242.
64. Winter G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 2010, 43:186-190.
65. Wu Y., West A.P., Kim H.J., Thornton M.E., Ward A.B., Bjorkman P.J. Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. Cell Rep. 2013, 10.1016/j.celrep.2013.11.015.